TAO Synergies TAOX
NASDAQ TAOX
$4.14 +0.13 (+3.24%)
As of: Sep 9, 2026 · 11:58 AM EDT

TAO Synergies (TAOX) Net Income towards Common Stockholders (2019 - 2026)

TAO Synergies' (TAOX) quarterly Net Income towards Common Stockholders came in at -$13.7 million in Q2 2026, up 22.48% on a YoY basis from -$11.2 million in Q2 2025, and down 509.51% quarter-over-quarter from $3.3 million in Q1 2026.

Analysis

TAO Synergies (TAOX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$13.7 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 22.48% year-over-year to -$13.7 million; the trailing twelve-month figure through Jun 2026 stood at -$22.1 million (up 24.32% YoY), and the FY2025 full-year result was -$29.1 million, down 114.45% from the prior year.
  • Net Income towards Common Stockholders fell to -$13.7 million in Q2 2026 per TAOX's latest filing, from $3.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $4.4 million in Q4 2022 and bottomed at -$17.6 million in Q2 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$4.0 million across 5 years, with a median of -$3.2 million in 2022.
  • The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders plunged 1573.58% in 2024, then jumped 1887.19% in 2026.
  • Over 5 years, Net Income towards Common Stockholders stood at $4.4 million in 2022, then tumbled by 128.16% to -$1.2 million in 2023, then sank by 360.0% to -$5.7 million in 2024, then tumbled by 37.43% to -$7.8 million in 2025, then plunged by 75.73% to -$13.7 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$13.7 million, $3.3 million, and -$7.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Amgen 211.88 Bn 197.89 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 181.55 Bn 178.37 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 132.31 Bn 124.45 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 82.51 Bn 74.52 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 61.54 Bn 56.36 Bn 1.37 Bn 472.00 Mn
6 Moderna 54.69 Bn 49.55 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 34.07 Bn 30.76 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.41 Bn 30.12 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 30.10 Bn 30.10 Bn 1.16 Mn -290.61 Mn
10 TAO Synergies 30.93 Mn 30.93 Mn - -13.66 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.66 Mn
Mar 31, 2026 3.34 Mn
Dec 31, 2025 -7.77 Mn
Sep 30, 2025 -3.97 Mn
Jun 30, 2025 -17.62 Mn
Mar 31, 2025 167,836.00
Dec 31, 2024 -5.66 Mn
Sep 30, 2024 -6.05 Mn
Jun 30, 2024 -1.43 Mn
Mar 31, 2024 -425,158.00
Dec 31, 2023 -1.23 Mn
Sep 30, 2023 -361,425.00
Jun 30, 2023 -10.21 Mn
Mar 31, 2023 -1.98 Mn
Dec 31, 2022 4.37 Mn
Sep 30, 2022 -3.03 Mn
Jun 30, 2022 -3.75 Mn
Mar 31, 2022 -3.28 Mn
Dec 31, 2021 -4.24 Mn
Sep 30, 2021 -2.93 Mn